Therapeutic implications of accurate classification of pituitary adenomas

Seminars in Diagnostic Pathology

Volumn 30, Issue 3, 2013, Pages 158-164

  Mete, Ozgur ^a,b   Asa, Sylvia L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Classification; Dopamine agonists; Pegvisomant; Pituitary adenoma; Somatostatin; Temozolomide

Indexed keywords

CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN RECEPTOR ALPHA; GROWTH HORMONE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEGVISOMANT; PROLACTIN; PROTEIN P53; RETICULIN; SOMATOSTATIN DERIVATIVE; STEROIDOGENIC FACTOR 1; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR TPIT; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ACTH SECRETING CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CUSHING DISEASE; DIAGNOSTIC ACCURACY; GAMMA KNIFE RADIOSURGERY; GONADOTROPIN SECRETING CELL; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROLACTINOMA; PROTEIN EXPRESSION; THYROTROPIN SECRETING ADENOMA; TREATMENT FAILURE; TSH SECRETING CELL; TUMOR CELL; TUMOR CLASSIFICATION;

CLASSIFICATION; DOPAMINE AGONISTS; PEGVISOMANT; PITUITARY ADENOMA; SOMATOSTATIN; TEMOZOLOMIDE;

ADENOMA; HUMANS; PITUITARY NEOPLASMS;

EID: 84885933960     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2013.06.002     Document Type: Article

References (33)

1. Asa S.L. Tumors of the pituitary gland. Fascicle 15. The Atlas of Tumor Pathology 2011, Armed Forces Institute of Pathology, Washington DC. 4th Series.
2. Ezzat S., Asa S.L., Couldwell W.T., Barr C.E., Dodge W.E., Vance M.L., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101:613-619.
3. Mete O., Asa S.L. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012, 22:443-453.
4. Mete O., Asa S.L. Pituitary adenomas, Pituitary gland. Diagnostic Pathology, Endocrine 2012, section 4:20-25. Amirsys, Salt Lake City, Utah.
5. Asa S.L. Practical pituitary pathology: what does the pathologist need to know?. Arch Pathol Lab Med 2008, 132:1231-1240.
6. Asa S.L., Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol 2009, 4:97-126.
7. Mete O., Ezzat S., Asa S.L. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 2012, 30(49):R69-R78.
8. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004.
9. Sánchez-Ortiga R., Sánchez-Tejada L., Moreno-Perez O., Riesgo P., Niveiro M., Picó Alfonso A.M. Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 2012, [Epub ahead of print].
10. Ezzat S., Zheng L., Asa S.L. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004, 18:2543-2552.
11. Hussaini I.M., Trotter C., Zhao Y., Abdel-Fattah R., Amos S., Xiao A., et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 2007, 170:356-365.
12. Salehi F., Agur A., Scheithauer B.W., Kovacs K., Lloyd R.V., Cusimano M. Ki-67 in pituitary neoplasms: a review-part I. Neurosurgery 2009, 65:429-437.
13. Salehi F., Agur A., Scheithauer B.W., Kovacs K., Lloyd R.V., Cusimano M. Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery 2010, 67:1790-1798.
14. Filippella M., Galland F., Kujas M., Young J., Faggiano A., Lombardi G., et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006, 65:536-543.
15. Al-Shraim M., Asa S.L. The 2004 World Health Organization classification of pituitary tumors: what is new?. Acta Neuropathol 2006, 111:1-7.
16. Al-Brahim N.Y., Asa S.L. My approach to pathology of the pituitary gland. J Clin Pathol 2006, 59:1245-1253.
17. Nosé V., Ezzat S., Horvath E., Kovacs K., Laws E.R., Lloyd R., et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011, 135(5):640-646.
18. Erickson D., Scheithauer B., Atkinson J., Horvath E., Kovacs K., Lloyd R.V., et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2009, 71:92-99.
19. Horvath E. Ultrastructural markers in the pathologic diagnosis of pituitary adenomas. Ultrastruct Pathol 1994, 18:171-179.
20. Horvath E., Kovacs K., Singer W., Ezrin C., Kerenyi N.A. Acidophil stem cell adenoma of the human pituitary. Arch Pathol Lab Med 1977, 101:594-599.
21. Horvath E., Kovacs K., Smyth H.S., Cusimano M., Singer W. Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 2005, 29:511-524.
22. Menucci M., Quiñones-Hinojosa A., Burger P., Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 2011, 14:68-74.
23. Velija-Asimi Z. The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy. Ther Adv Endocrinol Metab 2012, 3:3-9.
24. Katznelson L., Atkinson J.L., Cook D.M., Ezzat S.Z., Hamrahian A.H., Miller K.K. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 2011, 17(suppl 4):1-44.
25. Alahmadi H., Lee D., Wilson J.R., Hayhurst C., Mete O., Gentili F., et al. Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 2012, 154:1493-1498.
26. Yamada S., Ohyama K., Taguchi M., Takeshita A., Morita K., Takano K., et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 2007, 61:580-584.
27. Asa S.L., Digiovanni R., Jiang J., Ward M.L., Loesch K., Yamada S., et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 2007, 67:7505-7511.
28. Neggers S.J., van der Lely A.J. Pegvisomant and improvement of quality of life in acromegalic patients. Horm Res Paediatr 2011, 76(suppl 1):102-105.
29. Ezzat S., Gaspo R., Serri O., Ur E., Chik C.L. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Clin Invest Med 2009, 32:E265.
30. Syro L.V., Ortiz L.D., Scheithauer B.W., Lloyd R., Lau Q., Gonzalez R., et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011, 117(3):454-462.
31. McCormack A.I., Wass J.A., Grossman A.B. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011, 41:1133-1148.
32. von Deimling A., Korshunov A., Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21:74-87.
33. Salehi F., Scheithauer B.W., Kros J.M., Lau Q., Fealey M., Erickson D., et al. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 2011, 104:647-657.